Literature DB >> 14637096

Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice.

Véronique Blanchard1, Saliha Moussaoui, Christian Czech, Nathalie Touchet, Bruno Bonici, Michel Planche, Thierry Canton, Iness Jedidi, Micheline Gohin, Oliver Wirths, Thomas A Bayer, Dominique Langui, Charles Duyckaerts, Günter Tremp, Laurent Pradier.   

Abstract

Several novel transgenic mouse models expressing different mutant APPs in combination with mutant PS1 have been developed. These models have been analyzed to investigate the formation and progressive alterations of dystrophic neurites (DNs) in relation to Abeta deposits. In the most aggressive model, Abeta deposits appear as early as 2.5 months of age. Maturation of DNs was qualitatively quite similar among models and in some respect reminiscent of human AD pathology. From the onset of deposition, most if not all Abeta deposits were decorated with a high number of APP-, ubiquitin-, and MnSOD-immunoreactive DNs. Phosphorylated Tau DNs, however, appeared at a much slower rate and were more restricted. Mitochondrial dysfunction markers were observed in DNs: the frequency and the density per deposit of DNs accumulating cytochrome c, cytochrome oxidase 1, and Bax progressively increased with age. Later, the burden of reactive DNs was reduced around large compact/mature deposits. In addition, the previously described phenomenon of early intraneuronal Abeta accumulation in our models was associated with altered expression of APP protein as well as oxidative and mitochondrial stress markers occasionally in individual neurons. The present study demonstrates that oxidative and mitochondrial stress factors are present at several phases of Abeta pathology progression, confirming the neuronal dysfunction in APP transgenic mice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14637096     DOI: 10.1016/s0014-4886(03)00252-8

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  95 in total

1.  Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease.

Authors:  Géraldine Poisnel; Anne-Sophie Hérard; Nadine El Tannir El Tayara; Emmanuel Bourrin; Andreas Volk; Frank Kober; Benoit Delatour; Thierry Delzescaux; Thomas Debeir; Thomas Rooney; Jésus Benavides; Philippe Hantraye; Marc Dhenain
Journal:  Neurobiol Aging       Date:  2011-11-12       Impact factor: 4.673

2.  Building a more perfect beast: APP transgenic mice with neuronal loss.

Authors:  Dennis W Dickson
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

3.  Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model.

Authors:  Caty Casas; Nicolas Sergeant; Jean-Michel Itier; Véronique Blanchard; Oliver Wirths; Nicolien van der Kolk; Valérie Vingtdeux; Evita van de Steeg; Gwenaëlle Ret; Thierry Canton; Hervé Drobecq; Allan Clark; Bruno Bonici; André Delacourte; Jesús Benavides; Christoph Schmitz; Günter Tremp; Thomas A Bayer; Patrick Benoit; Laurent Pradier
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

Review 4.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

5.  Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist.

Authors:  Pooneh Memar Ardestani; Andrew K Evans; Bitna Yi; Tiffany Nguyen; Laurence Coutellier; Mehrdad Shamloo
Journal:  Neuropharmacology       Date:  2017-01-13       Impact factor: 5.250

Review 6.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Authors:  Masashi Kitazawa; Rodrigo Medeiros; Frank M Laferla
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

7.  Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis.

Authors:  Marzia Perluigi; Rukhsana Sultana; Giovanna Cenini; Fabio Di Domenico; Maurizio Memo; William M Pierce; Raffaella Coccia; D Allan Butterfield
Journal:  Proteomics Clin Appl       Date:  2009-06-01       Impact factor: 3.494

8.  Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits.

Authors:  Katharina Schindowski; Alexis Bretteville; Karelle Leroy; Séverine Bégard; Jean-Pierre Brion; Malika Hamdane; Luc Buée
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

9.  Increased T-cell reactivity and elevated levels of CD8+ memory T-cells in Alzheimer's disease-patients and T-cell hyporeactivity in an Alzheimer's disease-mouse model: implications for immunotherapy.

Authors:  Katharina Schindowski; Anne Eckert; Jürgen Peters; Corinna Gorriz; Uta Schramm; Thomas Weinandi; Konrad Maurer; Lutz Frölich; Walter E Müller
Journal:  Neuromolecular Med       Date:  2007-10-26       Impact factor: 3.843

10.  Gender dependent APP processing in a transgenic mouse model of Alzheimer's disease.

Authors:  S Schäfer; O Wirths; G Multhaup; T A Bayer
Journal:  J Neural Transm (Vienna)       Date:  2006-10-31       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.